Abstract
Laboratory and clinical studies on PC-904, a new semisynthetic penicillin, were performed with following results. PC-904 in doses of 30-50 mg/kg body weight was administered intravenously. The maximum blood level was reached at the end of administration (both in drip infusion and one-shot), and a dose response was observed. In two cases of drip infusion, peak levels were 271.1μg/ml and 88.9 μg/ml. The half-life in serum was estimated to be 53.4 minutes and 80.4 minutes, and the urinary recovery was 25.751 within 3 hours in one patient and 25.5% within 6 hours in the other, respectively. In a case of one shot intravenous injection, the peak level was 330.9μg/ml, the half-life was 88.2 minutes, and the urinary recovery was 39.691 within 3 hours.
Clinical evaluation of PC-904 was attempted in seven patients. The diagnosis were urinary tract infections in four cases, acute brorichitis in two, and acute purulent thyroiditis in one. Of four cases with urinary tract infections, two were treated successfully, although bacteriological effect was negative in one, one patient failed to improve, and the other one -could not be evaluated because of discontinuance of drug due to severe anaphylactic reaction. In two patients with acute bronchitis, clinical effects were obscure. In one case of acute purulent thyroiditis, treatment with this drug was terminated in early period because ihe laboratory study indicated other antibiotic to be more effective to the causative organism.
In conclusion, this drug was regarded as A effective in two.cases, ineffective in one and in the other four cases distinct evaluation was impossible.
